December 23, 2008 — In the treatment of advanced ovarian cancer, neoadjuvant chemotherapy before surgical debulking may be the new standard of care — especially in countries where the scheduling of a ...

Significant disparities exist in the adoption of minimally invasive interval debulking surgery for advanced ovarian cancer, with gaps potentially widening as the procedure becomes more common.

For patients with high-grade serous ovarian cancer, an aggressive form of the disease, surgery to remove the tumor before starting chemotherapy should lead to better outcomes than the reverse, ...

Stage 2 ovarian cancer is localized to the pelvis, with substages 2A and 2B indicating specific spread patterns. Diagnosis involves physical exams, imaging, blood tests, and biopsy to confirm cancer ...

Cancer outcomes are largely measured in terms of disease-free survival or overall survival, which is highly dependent on timely diagnosis and access to treatment methods available within the country's ...

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery. Increasing the number of chemotherapy ...

Mirvetuximab soravtansine (MIRV; Elahere; AbbVie) demonstrated significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer, showing particular promise in ...

New research in the October 2023 issue of JNCCN - Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as ...

Please provide your email address to receive an email when new articles are posted on . Laparoscopy may have some advantages over laparotomy for ovarian cancer. Results of this review are limited and ...

Study findings from this surgical case series may be useful in counseling men with high-risk prostate cancer features before choosing initial local treatment. Surgery remains a viable option as part ...

Diagnosed with advanced ovarian cancer in her late 40s, Lora Fox Gamble had few options for treatment until Dr. Don Dizon of the Lifespan Cancer Institute identified her as a candidate for a radical ...